Cantor Fitzgerald initiated coverage on Q32 Bio
$QTTB
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Q32 Bio with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/18/2026 | Overweight | Cantor Fitzgerald | |
| 2/25/2026 | $13.00 | Buy | H.C. Wainwright |
| 2/11/2025 | $22.00 → $3.00 | Outperform → Market Perform | BMO Capital Markets |
| 2/11/2025 | $20.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 12/11/2024 | Buy → Neutral | Guggenheim | |
| 12/11/2024 | $95.00 → $16.00 | Overweight → Equal Weight | Wells Fargo |
| 12/11/2024 | $90.00 → $22.00 | Strong Buy → Outperform | Raymond James |
| 12/11/2024 | $68.00 → $9.00 | Outperform → Market Perform | Leerink Partners |
Cantor Fitzgerald initiated coverage of Q32 Bio with a rating of Overweight
H.C. Wainwright initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $13.00
BMO Capital Markets downgraded Q32 Bio from Outperform to Market Perform and set a new price target of $3.00 from $22.00 previously
WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-fu
WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Q32 Bio intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissio
-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 ---- Q32
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
4 - Q32 Bio Inc. (0001661998) (Issuer)
SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)
S-3 - Q32 Bio Inc. (0001661998) (Filer)
8-K - Q32 Bio Inc. (0001661998) (Filer)
SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)
SC 13G - Q32 Bio Inc. (0001661998) (Subject)
SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)
-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 ---- Q32
-- Conference call to be held Monday, July 13th at 8:00 a.m. E.T. --WALTHAM, Mass., July 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA on Monday, July 13, 2026. Following the announcement, Q32 Bio will host a conference call and webcast at 8:00 a.m. E.T. on Monday, July 13, 2026 to discuss the results.Conference CallQ32 Bio's live conference call an
WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent